(±)-Methadone (hydrochloride) (Item No. ISO00145) is an analytical reference material categorized as an opioid. (±)-Methadone has analgesic activity. Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.
Controlled substance (opiate). Methadone hydrochloride is used in treatment of opioid dependence.
Diphenylacetonitrile is condensed with 2-chloro-1-dimethylaminopropane to give 4-(dimethylamino)-2,2-diphenyl valeronitrile. It is then reacted with ethyl magnesium bromide and then hydrolyzed using HCl to give methadone hydrochloride.
Dolophine Hydrochloride (Roxane); Dolophine Hydrochloride (Xanodyne);
Methadose (Mallinckrodt); Westadone (Sandoz).
Toxic. Addictive narcotic. Use restricted.
Treatment of opioid drug addiction
Analgesic for moderate to severe pain
Metabolised in the liver to the Potentially hazardous interactions with other drugs
Analgesics: possible opioid withdrawal with
buprenorphine and pentazocine.
Antibacterials: metabolism increased by rifampicin;
increased risk of ventricular arrhythmias with
delamanid and telithromycin.
Antidepressants: concentration possibly increased
by fluoxetine, fluvoxamine, paroxetine and sertraline;
possible CNS excitation or depression with MAOIs
and moclobemide - avoid; possibly increased
sedative effects with tricyclics; concentration possibly
reduced by St John's wort.
Antiepileptics: concentration reduced by
carbamazepine, phenobarbital and phenytoin.
Antifungals: concentration increased by fluconazole,
ketoconazole, voriconazole and possibly itraconazole
- may need to reduce methadone dose with
voriconazole, avoid with ketoconazole.
Antihistamines: increased sedative effects with
sedating antihistamines.
Antimalarials: increased risk of ventricular
arrhythmias with piperaquine with artenimol -
avoid.
Antipsychotics: enhanced hypotensive and sedative
effects; increased risk of ventricular arrhythmias with
antipsychotics that prolong the QT interval - avoid
with amisulpride.
Antivirals: methadone possibly increases
concentration of zidovudine; concentration
reduced by efavirenz, fosamprenavir and ritonavir;
concentration possibly reduced by abacavir,
nevirapine and rilpivirine; concentration possibly
affected by boceprevir; concentration of didanosine
possibly reduced; increased risk of ventricular
arrhythmias with saquinavir and telaprevir - avoid
with saquinavir and use with caution with telaprevir.
Atomoxetine: increased risk of ventricular
arrhythmias.
Cytotoxics: possible increased risk of ventricular
arrhythmias with bosutinib, ceritinib, panobinostat
and vandetanib.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate
- avoid
Metabolised in the liver to the major metabolite
2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine
and the minor metabolite 2-ethyl-3,3-diphenyl-5-
methylpyrrolidine, both of them inactive. Two other
metabolites have also been identified.
These metabolites are excreted in the faeces and urine
with unchanged methadone
The salt crystallises from EtOH, or EtOH/Et2O.
